Structure-based design of novel dihydroisoquinoline BACE-1 inhibitors that do not engage the catalytic aspartates.

The structure-activity relationship of a series of dihydroisoquinoline BACE-1 inhibitors is described. Application of structure-based design to screening hit 1 yielded sub-micromolar inhibitors. Replacement of the carboxylic acid of 1 was guided by X-ray crystallography, which allowed the replacement of a key water-mediated hydrogen bond. This work culminated in compounds such as 31, which possess good BACE-1 potency, excellent permeability and a low P-gp efflux ratio.

[1]  James E Audia,et al.  Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor , 2011, The Journal of Neuroscience.

[2]  P. Oates,et al.  Sorbitol dehydrogenase inhibitors (SDIs): a new potent, enantiomeric SDI, 4-[2-1R-hydroxy-ethyl)-pyrimidin-4-yl]piperazine-1-sulfonic acid dimethylamide. , 2001, Journal of medicinal chemistry.

[3]  John-Michael Sauer,et al.  Design and synthesis of cell potent BACE-1 inhibitors: structure-activity relationship of P1' substituents. , 2009, Bioorganic & medicinal chemistry letters.

[4]  Hannes A. Braun,et al.  Inhibitors and Modulators of β- and γ-Secretase , 2006 .

[5]  É. Hajós‐Korcsok,et al.  Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors. , 2012, Journal of medicinal chemistry.

[6]  N. Meanwell.  Synopsis of some recent tactical application of bioisosteres in drug design. , 2011, Journal of medicinal chemistry.

[7]  M. Gleeson.  Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.

[8]  C. Mathers,et al.  Global prevalence of dementia: a Delphi consensus study , 2005, The Lancet.

[9]  Ying-zi Xu,et al.  Small-molecule BACE1 inhibitors: a patent literature review (2006 – 2011) , 2012, Expert opinion on therapeutic patents.

[10]  Rajiv Chopra,et al.  Design and synthesis of 5,5'-disubstituted aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors. , 2010, Journal of medicinal chemistry.

[11]  W. Richards,et al.  Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation , 2001, Nature Neuroscience.

[12]  Joseph B. Moon,et al.  Design, synthesis, and crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitors of human beta-secretase. , 2007, Journal of medicinal chemistry.

[13]  H. Sham,et al.  Design, synthesis, and structure-activity relationship of novel orally efficacious pyrazole/sulfonamide based dihydroquinoline gamma-secretase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[14]  P. Verhoest,et al.  Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. , 2010, ACS chemical neuroscience.

[15]  G. Tóth,et al.  Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: structure-activity relationship of the aryl region. , 2010, Bioorganic & medicinal chemistry letters.

[16]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[17]  K. Kandeel,et al.  Behavior of 3-benzylamino-5-aryl-2(3H)-furanones towards some nitrogen nucleophiles , 2006 .

[18]  Lingyan Wang,et al.  Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation. , 2010, Journal of medicinal chemistry.

[19]  H. Sham,et al.  Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. , 2010, Bioorganic & medicinal chemistry letters.

[20]  I. Kola,et al.  BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. , 2001, Human molecular genetics.

[21]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[22]  H. Cai,et al.  BACE1 is the major β-secretase for generation of Aβ peptides by neurons , 2001, Nature Neuroscience.

[23]  I. Lieberburg,et al.  Cellular mechanisms of beta-amyloid production and secretion. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Motter,et al.  Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. , 2010, Bioorganic & medicinal chemistry letters.

[25]  T. Belliotti,et al.  The preparation of optically active α-amino 4H-[1,2,4]oxadiazol-5-ones from optically active α-amino acids , 2009 .

[26]  William Greenlee,et al.  Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation. , 2012, Journal of medicinal chemistry.

[27]  M. Citron,et al.  BACE1 (β-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time , 2003, Neurobiology of Disease.